Idelalisib and riTUXimab Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Idelalisib and riTUXimab Therapy, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	TP53 deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	TP53 somatic variants	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab
Sensitivity (+)	17p deletion	Chronic Lymphocytic Leukemia	Idelalisib, Rituximab